Cílený transport platinových cytostatik
Since their introduction in 1970's platinum complexes represent one of the most significant groups of chemotherapeutics. These drugs represented by Cisplatin and Oxaliplatin complexes exhibit high efficiency against many solid tumors. Serious side effects such as neurotoxicity, nephrotoxicity and gradual initiation cell resistance limit the use of platinum drugs in cancer treatment. Current research aims to mitigate these side effects through the introduction 4th generation platinum cytostatics and through the preparation of advanced dosage forms allowing for target delivery of current cytostatics. In this review, currently developed and clinically tested transport systems, prepared for the target delivery of platinum cytostatics either via active or passive transport, are summarized.